Laurus Labs
Ticker > Company >

Laurus Labs share price

Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  2.91 L   1.9 K   496

918.60
+25.10 (2.81%)
BSE: Today, 02:56 PM

Price Summary

Today's High

₹ 921

Today's Low

₹ 876.1

52 Week High

₹ 922.55

52 Week Low

₹ 422.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 49588.32 Cr.

Enterprise Value

₹ 51862.32 Cr.

No. of Shares

53.98 Cr.

P/E

97.32

P/B

10.56

Face Value

₹ 2

Div. Yield

0.13 %

Book Value (TTM)

₹  86.99

CASH

₹ 50.64 Cr.

DEBT

₹ 2324.64 Cr.

Promoter Holding

27.59 %

EPS (TTM)

₹  9.44

Sales Growth

8.41%

ROE

8.72 %

ROCE

10.44%

Profit Growth

70.04 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Laurus Labs Ltd.

Lasinone Trilawil Prolavir LR Trilavir Mini Myvajra

Index Presence

The company is present in 26Indices.

NIFTYALPHA

Nifty Alpha 50
51964.85
  -42.8499999999985 (-0.0823916458524421%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
45196.45
  449.299999999996 (1.00408629376396%)

NIFTY500

Nifty 500
23491.55
  46.3499999999985 (0.197695050586044%)

NIFTYPHARMA

Nifty Pharma
22568.9
  327.550000000003 (1.47270736713376%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20304.25
  27.0999999999985 (0.133647973211226%)

NIFTYSMALL

NIFTY Smallcap 100
18468.85
  45.6499999999978 (0.247785401016087%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18100.25
  26 (0.143851058826794%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17470.75
  0 (0%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16393.45
  26.8000000000011 (0.163747620924259%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
15926.8
  16.1999999999989 (0.101818913177376%)

NIFTYHEALTH

Nifty Healthcare Index
14849.35
  189.800000000001 (1.2947191421292%)

NFT500EQUAL

Nifty 500 Equal Weight
14645.35
  6.35000000000036 (0.0433772798688503%)

NIFTYTOTALMCAP

Nifty Total Market index
13222.8
  23.7999999999993 (0.180316690658389%)

NIFTYSMALLCAP50

Nifty Smallcap 50
8891
  42.5499999999993 (0.48087518152895%)

NIFTYFULLSMALLCAP100

NIFTY FULL SMALLCAP100
4000.01
  -72.2099999999996 (-1.77323425551663%)

MIDCAP

S&P Bse Mid Cap
46863.85
  121.830000000002 (0.260643421058826%)

BSE HC

S&P Bse Healthcare
45105.8
  367.07 (0.820474787728664%)

BSE500

S&P Bse 500
36898.69
  85.5600000000049 (0.232417075103375%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12305.67
  14.0699999999997 (0.114468417455815%)

BSE1000

Bse 1000
10995.93
  23.7000000000007 (0.215999846886183%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

S&P Bse 250 SmallCap
6984.58
  -3.96000000000004 (-0.0566641959550918%)

SPBSMOIP

S&P Bse Momentum
2287.06
  9.38000000000011 (0.411822556285357%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.41%
3 Year3.49%
5 Year13.28%

Profit Growth

1 Year70.04%
3 Year-20.25%
5 Year7.33%

ROE%

1 Year8.72%
3 Year11.55%
5 Year20.32%

ROCE %

1 Year10.44%
3 Year13.42%
5 Year20.48%

Debt/Equity

0.5123

Price to Cash Flow

91.82

Interest Cover Ratio

3.7651

CFO/PAT (5 Yr. Avg.)

1.17159121624922

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 27.59 2.69
Mar 2025 27.62 2.69
Dec 2024 27.62 2.69
Sep 2024 27.18 0.00
Jun 2024 27.18 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 23.6628477357467% in the last 5 years.
  • The company has a good cash flow management; CFO/PAT stands at 1.17159121624922.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.46757215951611.

 Limitations

  • The company has shown a poor profit growth of -20.2546738551189% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.48806787274689% for the Past 3 years.
  • The company is trading at a high PE of 97.32.
  • The company is trading at a high EV/EBITDA of 41.3638.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1116.93 1184.85 1265.19 1650.01 1432.75
Total Expenditure 955.54 1003.02 1058.91 1255.18 1105.37
Operating Profit 161.39 181.83 206.28 394.83 327.38
Other Income 9.3 11.89 7.12 72.16 21.52
Interest 40.89 44.69 48.02 48.6 43.89
Depreciation 91 90.94 88.66 88.19 93.57
Exceptional Items 0 0 0 0 0
Profit Before Tax 38.8 58.09 76.72 330.2 211.44
Tax 10.02 15.65 19.45 78.3 53.5
Profit After Tax 28.78 42.44 57.27 251.9 157.94
Adjusted EPS (Rs) 0.53 0.79 1.06 4.67 2.93

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 4768.72 4707.04 5773.45 4812.39 5216.98
Total Expenditure 3258.85 3421.84 4291.69 4062.51 4272.65
Operating Profit 1509.87 1285.2 1481.76 749.88 944.33
Other Income 27.32 21.55 15.95 47.42 100.47
Interest 65.92 95.86 145.7 150.82 182.2
Depreciation 196.64 235.48 300.58 345.01 358.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 1274.63 975.41 1051.43 301.47 503.81
Tax 318.52 225.32 291.05 77.77 123.42
Net Profit 956.11 750.09 760.38 223.7 380.39
Adjusted EPS (Rs.) 17.82 13.96 14.12 4.15 7.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 107.32 107.47 107.73 107.79 107.85
Total Reserves 2604.92 3280.74 3949.09 4099.26 4456.1
Borrowings 382.64 549.67 565.49 490.53 414.25
Other N/C liabilities 178.68 236.55 229.33 234.11 446.51
Current liabilities 2696.26 2899.57 2844.09 3545.04 4109.3
Total Liabilities 5969.82 7074 7695.73 8476.73 9534.01
Assets
Net Block 1818.04 2186.23 2884.16 3036.31 2887.5
Capital WIP 324.17 755.03 357.06 155.51 336.24
Intangible WIP 0 0 0 0 0
Investments 318.89 361.72 384.12 634.87 740.22
Loans & Advances 91.84 69.82 132.84 292.11 591.9
Other N/C Assets 30.8 31.16 28.52 31.57 24.11
Current Assets 3386.08 3670.04 3909.03 4326.36 4954.04
Total Assets 5969.82 7074 7695.73 8476.73 9534.01
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1274.63 975.41 1051.43 301.47 503.81
Adjustment 240.43 322.36 442.51 478.32 498.63
Changes in Assets & Liabilities -594.55 -308.46 -344.26 -23.27 -327.99
Tax Paid -226.06 -166.34 -268.13 -97.98 -134.39
Operating Cash Flow 694.45 822.97 881.55 658.54 540.06
Investing Cash Flow -899.68 -836.61 -735.27 -756.74 -591.65
Financing Cash Flow 243.13 15.19 -185.19 139.41 59.32
Net Cash Flow 37.9 1.55 -38.91 41.21 7.73

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 27.18 27.18 27.62 27.62 27.59
chandrakanth chereddi 0.01 0.01 0.01 0.01 0.01
chava narasimha rao 0.02 0.02 0.02 0.02 0.02
chunduru venkata lakshman... 2.49 2.49 2.65 2.65 2.65
hymavathi vantaram 0.04 0.04 0.04 0.04 0.04
kamala kommana 0.02 0.02 0.02 0.02 0.02
krishnaveni vasireddi 0.04 0.04 0.04 0.04 0.04
m/s. leven holdings (repr... 1.24 1.24 1.24 1.24 1.24
m/s. nsn holdings (repres... 23.02 23.02 23.02 23.02 22.99
nagamani thokala 0.02 0.02 0.02 0.02 0.02
narasimha rao suryadevara... 0.03 0.03 0.03 0.03 0.03
rama suryadevara 0.03 0.03 0.03 0.03 0.03
satyanarayana chava - - 0.29 0.29 0.29
sekhar babu chunduru 0.02 0.02 0.02 0.02 0.02
venkata ravi kumar vantar... 0.19 0.19 0.19 0.19 0.19
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 72.82 72.82 72.38 72.38 72.41
akash bhanshali 1.33 1.33 1.33 1.33 1.32
anukar projects private l... 3.24 3.24 3.24 3.24 3.24
barclays wealth trustees ... 1.21 1.14 1.14 1.14 1.61
kotak funds - india midca... 1.33 1.39 1.39 1.16 1.13
life insurance corporatio... 2.70 2.70 2.70 2.70 2.17
new world fund inc 6.50 6.50 6.50 6.50 6.49
sbi arbitrage opportuniti... - - - 1.82 1.64
smallcap world fund, inc 4.09 4.09 4.25 4.25 4.25
dsp arbitrage fund - - - 1.16 -
goldman sachs funds - gol... - - 1.18 1.18 -
vanguard total internatio... - 1.00 1.00 1.02 -
dsp equity opportunities ... - - 1.25 - -
sbi large & midcap fund - 2.53 2.11 - -
amansa holdings private l... 2.21 2.14 - - -
mirae asset elss tax save... 5.24 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit FITCH
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21
Presentation H1FY24

Company News

Laurus Labs informs about investor presentation 12 Sep, 4:59 PM Laurus Labs receives 531.77 acres of land from Government of Andhra Pradesh 28 Jul, 12:37 PM Laurus Labs - Quaterly Results 25 Jul, 3:06 PM Laurus Labs - Quaterly Results 25 Jul, 3:06 PM Laurus Labs - Quaterly Results 25 Jul, 3:06 PM Laurus Labs invests Rs 39.99 crore in Laurus Bio 26 Jun, 3:08 PM Laurus Labs informs about investor conference 12 Jun, 5:27 PM Laurus Labs - Quaterly Results 24 Apr, 3:00 PM Laurus Labs - Quaterly Results 24 Apr, 3:00 PM Laurus Labs - Quaterly Results 24 Apr, 3:00 PM Laurus Labs gets EIR for API manufacturing facility in Andhra Pradesh 15 Apr, 2:18 PM Laurus Labs gets nod to acquire up to 26% stake in Kurnool Renewables 28 Mar, 4:40 PM Laurus Labs acquires equity shares in KRKA 17 Mar, 11:22 AM Laurus Labs - Quaterly Results 24 Jan, 2:58 PM Laurus Labs - Quaterly Results 24 Jan, 2:58 PM Laurus Labs - Quaterly Results 24 Jan, 2:58 PM Laurus Labs’ arm gets one observation from USFDA 23 Jan, 11:58 AM Laurus Labs’ arm secures equity investments from Eight Roads Ventures, F-Prime Capital, Laurus Labs 9 Dec, 10:50 AM Laurus Labs submits analyst meet intimation 7 Nov, 12:43 PM Laurus Labs informs about standalone and consolidated financial results 24 Oct, 5:21 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs inaugurates new R&D facility 16 Sep, 2:59 PM Laurus Labs completes USFDA Audit for API Manufacturing Facility at Hyderabad 14 Sep, 4:47 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs informs about analyst meet 19 Jul, 5:12 PM Laurus Labs informs about press release 19 Jun, 4:32 PM Laurus Labs informs about disclosures 11 Jun, 4:29 PM Laurus Lab informs about approval of audited financial results 25 Apr, 5:12 PM Laurus Labs informs about investors presentation 25 Apr, 4:50 PM Laurus Labs informs about press release 25 Apr, 4:45 PM Laurus Labs reports 30% fall in Q4 consolidated net profit 25 Apr, 4:00 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM USFDA completes inspection at Laurus Labs’ API manufacturing facilities 19 Apr, 6:16 PM Laurus Labs informs about closure of trading window 30 Mar, 10:16 AM Laurus Labs invests over Rs 99 crore in subsidiary 19 Feb, 12:13 PM Laurus Labs informs about updates on acquisition 17 Feb, 3:14 PM Laurus Labs submits analyst meet intimation 13 Feb, 3:56 PM Laurus Labs enters into joint venture agreement with Krka 29 Jan, 12:41 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs informs about board meeting 17 Jan, 3:22 PM USFDA inspects Andhra Pradesh facility of Laurus Labs’ arm 13 Dec, 10:41 AM Laurus Labs informs about investor presentation 25 Nov, 11:53 AM

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Laurus Labs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Laurus Labs has a PE ratio of 94.192304432579 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Laurus Labs has ROA of 4.224% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Laurus Labs has a Current ratio of 1.2056.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Laurus Labs has a ROE of 8.721%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Laurus Labs has a Debt to Equity ratio of 0.5123 which means that the company has low proportion of debt in its capital.

  • Sales growth: Laurus Labs has reported revenue growth of 8.4073% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Laurus Labs for the current financial year is 18.1010853022247%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Laurus Labs is Rs 1.2 and the yield is 0.1343%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Laurus Labs is Rs 9.4392. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Laurus Labs in Ticker for free. Also, one can get the intrinsic value of Laurus Labs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Laurus Labs FAQs

Q1. What is Laurus Labs share price today?
Ans: The current share price of Laurus Labs is Rs 889.1.

Q2. What is the market capitalisation of Laurus Labs?
Ans: Laurus Labs has a market capitalisation of Rs 47995.83177009 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Laurus Labs?
Ans: The PE ratio of Laurus Labs is 94.192304432579 and the P/B ratio of Laurus Labs is 10.2206092821203, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Laurus Labs share?
Ans: The 52-week high share price of Laurus Labs is Rs 922.5, and the 52-week low share price of Laurus Labs is Rs 427.05.

Q5. Does Laurus Labs pay dividends?
Ans: Currently, Laurus Labs pays dividends. Dividend yield of Laurus Labs is around 0.1343%.

Q6. What are the face value and book value of Laurus Labs shares?
Ans: The face value of Laurus Labs shares is Rs 2, while the book value per share of Laurus Labs is around Rs 86.9909. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Laurus Labs?
Ans: Laurus Labs has a total debt of Rs 2324.64 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Laurus Labs?
Ans: The ROE of Laurus Labs is 8.721% and ROCE of Laurus Labs is 10.4378%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Laurus Labs a good buy for the long term?
Ans: The Laurus Labs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Laurus Labs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Laurus Labs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Laurus Labs’s financials?
Ans: You can review Laurus Labs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Laurus Labs

Laurus Labs Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Laurus Labs Ltd. is a renowned pharmaceutical company that specializes in the research, development, and manufacturing of generic APIs (Active Pharmaceutical Ingredients) and research and development (R&D) services to the global pharmaceutical industry. Here, we will delve into Laurus Labs Ltd.'s various aspects, including its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders. This analysis is tailored specifically for long-term stock investors seeking comprehensive stock evaluation. Additionally, we will highlight the use of Ticker pre-built screening tools that support fair value calculation through DCF (Discounted Cash Flow) Analysis, BVPS (Book Value per Share) Analysis, Earnings Multiple Approach, and DuPont Analysis.

Laurus Labs Ltd Share Price

Laurus Labs Ltd.'s share price is a key parameter for investors interested in long-term stock analysis. It is crucial to monitor and track the company's share price, which can be done through our trading platform. Laurus Labs Ltd. is traded on various stock exchanges, such as the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange), and investing in its shares can be done through these exchanges.

Laurus Labs Ltd Balance Sheet

The balance sheet is an essential financial statement that provides insights into Laurus Labs Ltd.'s assets, liabilities, and shareholder's equity at a particular point in time. It serves as a snapshot of the company's financial health and stability and is of utmost importance to long-term investors. Ticker innovative screening tools enable investors to calculate fair value using DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, thereby empowering them to make informed investment decisions.

Laurus Labs Ltd Annual Report

Laurus Labs Ltd.'s annual report is a comprehensive document that offers details about the company's performance, strategies, and governance in the preceding year. Ticker simplifies access to these annual reports, making them easily downloadable for investors' convenience. Studying the annual reports is crucial as it provides insights into the company's business model, growth trajectory, and future plans, enabling investors to gain a deeper understanding of Laurus Labs Ltd.

Laurus Labs Ltd Dividend

As a reputable company, Laurus Labs Ltd. values its shareholders and regularly distributes dividends to them. Dividends are a portion of the company's profits paid out to shareholders as a return on their investment. At our platform, investors can explore the company's dividend history and stay updated on the latest dividend announcements.

Laurus Labs Ltd Quarterly Results

To analyze Laurus Labs Ltd.'s financial performance over specific periods, it is necessary to review the company's quarterly results. Ticker offers a range of tools and resources to facilitate this analysis. Investors can access quarterly reports, utilize analytical tools, and employ pre-built screening tools to assess the company's growth trends, profitability, and overall financial stability.

Laurus Labs Ltd Stock Price

Monitoring stock prices is pivotal for investors aiming to buy or sell shares of Laurus Labs Ltd. Ticker platform delivers real-time stock price data, ensuring that investors have access to the latest information to make informed decisions. Along with the stock price, investors can closely track its fluctuations, historical trends, and trading volumes to evaluate the stock's performance.

Laurus Labs Ltd Price Chart

Price charts provide graphical representations of a stock's historical price movements, helping investors identify trends and patterns. Ticker offers comprehensive price charts of Laurus Labs Ltd., allowing investors to visualize the stock's performance over time.

Laurus Labs Ltd News

Keeping abreast of the latest news about Laurus Labs Ltd. is vital for long-term investors. Our platform provides up-to-date news, including market changes, corporate announcements, industry developments, and other relevant events that may impact the stock market. Investors can access these news updates to stay informed and make well-informed investment decisions.

Laurus Labs Ltd Concall Transcripts

Conference call transcripts provide valuable insights into Laurus Labs Ltd.'s management discussions regarding financial results, operational strategies, and future plans. By offering access to concall transcripts, our platform ensures that investors have access to first-hand information about the company's direction and future prospects.

Laurus Labs Ltd Investor Presentations

Laurus Labs Ltd. presents its corporate strategies, financial performance, and future projections through investor presentations. These presentations offer a glimpse into the company's growth plans, market positioning, and operational strategies. Ticker provides the facility to download these presentations, enabling investors to make well-informed decisions based on a comprehensive understanding of the company's objectives.

Laurus Labs Ltd Promoters

Promoters play a pivotal role in the success of Laurus Labs Ltd. They are individuals or entities responsible for starting the company, raising capital, and maintaining management control. Understanding the promoters' vision, strategies, and plans for the company's future is integral to evaluating the investment potential of Laurus Labs Ltd.

Laurus Labs Ltd Shareholders

Shareholders are critical stakeholders in any company. They provide the necessary capital and possess ownership through shares. Identifying the major shareholders of Laurus Labs Ltd., along with their respective stakes and voting power, is indispensable for assessing the company's governance structure and overall stability.

Laurus Labs Ltd ROCE

Laurus Labs Ltd ROCE (Return on Capital Employed) is a vital financial ratio used to evaluate the company's profitability in relation to the capital it employs. By analyzing the ROCE data available in the financials table or ratio section above, investors can gain insights into how effectively Laurus Labs Ltd generates returns on its capital investments. This ratio serves as a key indicator of the company's capital efficiency and overall profitability, making it an essential metric for stock analysis.

Laurus Labs Ltd EBITDA

Laurus Labs Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a significant financial measure that reflects the company's operational profitability. By excluding non-operating expenses, the EBITDA data available in the financials table or ratio section above provides insights into Laurus Labs Ltd's core business performance and operational efficiency.

Laurus Labs Ltd DPS

Laurus Labs Ltd DPS (Dividends Per Share) represents the cash distributed to shareholders for each share held in the company. Investors can evaluate Laurus Labs Ltd's dividend policy and potential returns by referring to the DPS data available in the financials table or ratio section above. This metric is particularly important for those seeking regular income from their investments.

Laurus Labs Ltd EPS

Laurus Labs Ltd EPS (Earnings Per Share) is a fundamental metric that indicates the company's profitability on a per-share basis. By analyzing the EPS data available in the financials table or ratio section above, investors can assess Laurus Labs Ltd's earning potential and performance. EPS is a significant measure used to evaluate the value and growth potential of the company's stock. 

Laurus Labs Balance Sheet Analysis

Laurus Labs has shown considerable growth and adaptation as reflected in its balance sheet from March 2020 to March 2024.

Laurus Labs' Equity and Liabilities

The company’s share capital has slightly increased from Rs 106.91 Cr in March 2020 to Rs 107.79 Cr by March 2024. There has been a significant increase in total reserves, up from Rs 1,708.89 Cr in 2020 to Rs 4,099.26 Cr in 2024, indicating a strong retention of earnings. Borrowings have also seen an increase from Rs 165 Cr in 2020 to a peak of Rs 565.49 Cr in 2023, before a slight decrease to Rs 490.53 Cr in 2024, suggesting adjustments in the company’s leverage strategy over the years.

Laurus Labs' Assets

The Net Block of Laurus Labs has increased from Rs 1,694.18 Cr in 2020 to Rs 3,036.31 Cr in 2024, showing a commitment to expanding fixed assets. Similarly, Investments have grown from Rs 58.32 Cr to Rs 634.87 Cr, illustrating a strategic deployment of funds into lucrative assets. Current assets have substantially grown from Rs 1,784.64 Cr in 2020 to Rs 4,326.36 Cr in 2024, which reflects positively on the liquidity measures taken by the company.

This analysis represents the standalone balance sheet of Laurus Labs, which offers insights into its financial health and strategical positioning in the pharmaceutical sector, crucial for investors and market watchers tracking NSE/BSE indices.

Read More
X